Latest total current liabilities for PASG: $20M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Passage Bio (PASG) currently reports a total current liabilities of $20M as of March 2026. That compares with $18M in the prior-year period — up 12.8% year over year. Use the charts on this page to explore Passage Bio's total current liabilities history and peer comparisons.
Passage Bio's total current liabilities increased from $18M to $20M — a 12.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Passage Bio reported $20M in total current liabilities as of March 2026. That compares with $18M in the prior-year period — up 12.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Passage Bio, and consider following PASG for alerts when major investors trade the stock.
Passage Bio is classified in the Healthcare sector. On total current liabilities, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PASG with unrelated industries.